NCT06360068View on ClinicalTrials.gov

A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 6, 2024

Primary Completion Date

May 1, 2025

Study Completion Date

May 1, 2025

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

Sulfasalazine Tablets

All subjects who meet the inclusion/exclusion criteria will be given sulfasalazine 750mg/dose, twice a day. The dosage will be increased to 1000mg/dose within one month, twice a day if the patient tolerates well.

All Listed Sponsors
lead

Qiong Fu

OTHER